Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — J.P. Morgan Annual Healthcare Conference 2017
24 slides from Dr. Reddy's Laboratories's conference presentation, 2017
Slide 1: J.P. Morgan Annual Healthcare Conference 2017
J.P. Morgan Annual Healthcare Conference 2017 Alok Sonig EVP & Head North America Generics
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Contents
Contents Company Purpose Update on US FDA Matter Sustainable Performance over Five Years Growth Roadmap Optimistic Future 3
Slide 4: Our Purpose
Our Purpose We accelerate access to affordable and innovative medicines Because Good Health Can’t Wait.
Slide 5: Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices
Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices PURPOSE OUR STRATEGIC CHOICES OUR PROMISES Bringing expensive First-to-market, medicine within tough-to-make reach products Addressing unmet We accelerate Differentiated patient needs formulations for access to a
Slide 6: Update on ongoing FDA matters
Update on ongoing FDA matters Nov Dec Jan Mar May Aug Dec 2015 2015 2016 2016 2016 2016 2016 Warning Letter Response First status Second status Third status Final status FDA Meeting For Three Sites Submitted update update update update Independent product quality assessments All the commitments as p
Slide 7: Sustainable Performance Over Five Years
SUSTAINABLE PERFORMANCE OVER FIVE YEARS 7
Slide 8: Sustainable Revenue Growth Over Last 5 Years
Sustainable Revenue Growth Over Last 5 Years REVENUES (Rs Cr) REVENUE CONTRIBUTION across Geographies - FY16 (%) +10% WELL PLACED TO HARNESS PROFITABLE 14,819 15,471 GROWTH OPPORTUNITIES IN THE FUTURE 11 13,217 11,627 11 NORTH AMERICA 9,674 INDIA RUSSIA & OTHER CIS 9 53 EUROPE REST OF THE WORLD 15 F
Slide 9: 2016 Highlights
2016 Highlights North America: Steady base business despite headwinds of pricing 1 pressures and limited launches; Acquisition of Teva and Ducere Portfolio India: Despite price controls, business has delivered robust growth 2 accelerated by successful UCB Integration and Amgen deal expansion Russia:
Slide 10: Growth Roadmap
Growth Roadmap e 4 ©
Slide 11: Robustly positioned to drive long-term profitable growth through diversified business model
Robustly positioned to drive long-term profitable growth through diversified business model Address unmet patient needs Proprietary through innovative solutions products Unbranded Biologics Generics Globalized Pipeline of First-to- R&D market, tough-to-make Maximizing value in products & Emerging ma
Slide 12: Well-positioned for long-term profitable growth
Well-positioned for long-term profitable growth Current FY18 - 21 FY22-25 NAG: NAG: Complex Injectables, Patches/ Topicals 505 b2 Generics, C2s OTC Brands Non-substitutable Generics Strong and proven track record India: India: across our base businesses Ramp-up Biosimilars business throu
Slide 13: Globalized R&D leverages Global Talent to address our complex scientific challenges
Globalized R&D leverages Global Talent to address our complex scientific challenges Complex Complex Injectable Chemistry Centre Centre of of Excellence Excellence Cambridge, UK Leiden, Netherlands Canada Germany UK USA Italy Product Development Complex Centres Generics & Hyperabad & Bangalore Propri
Slide 14: North America Generics: Consistent growth driven by limited competition products
North America Generics: Consistent growth driven by limited competition products STRATEGIC FOCUS Investments in Product Portfolio & Partnerships Base Business has grown at 15% Build capabilities for Complex dosage forms CAGR since FY12 (FY16 Gr:12%) Augment capacities for Oral Solids and Injec
Slide 15: Healthy Pipeline of First-to-market, Tough-to-make Products
Healthy Pipeline of First-to-market, Tough-to-make Products Bringing Expensive Medicines within Reach NUMBER OF PENDING Gx FILINGS BY PIPELINE HIGHLIGHTS DOSAGE FORM Topical/ 83 pending ANDAs & 2 pending NDAs (505b2s) Transdermal, 4 Acq. ANDAs (Teva), 7 No incl. 56 para-IV and 19 first to file pro
Slide 16: India business: Robust growth driven by successful new business integration
India business: Robust growth driven by successful new business integration STRATEGIC FOCUS Building differentiated portfolio of Business grew at 12% CAGR since brands and services FY12 (FY16 Gr:19%) Portfolio augmentation and productivity Successful integration of UCB improvement acquisition;
Slide 17: Russia Business: Fundamental demand for our brands continues to be strong
Russia Business: Fundamental demand for our brands continues to be strong with more stable Macro Economic Conditions STRATEGIC FOCUS Building differentiated portfolio of Strong revival in base business brands and patient-centric performance with ruble stabilization services Established strong pr
Slide 18: Biologics: Maximizing value of current assets in near to mid-term while pursuing global development
Biologics: Maximizing value of current assets in near to mid-term while pursuing global development EU/US Clinial BIOLOGICS REVENUE HAS GROWN AT APPROX. programs forRituximab and 35% CAGR OVER THE LAST 10 YEARS Peg-GCSF 4 Peg-grafeel® Dr. Reddy’s peg filgrastim launched; 3 Cresp® End-to-end Dr. Redd
Slide 19: Biologics: Creating substantial value in long term from new portfolio choices
Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity 6 existing products; > 50 filings across 14 major countries FY20 Product Portfolio 5 new products in clinical development 5 new products in early development Emerging Markets Revenue: $150Mn
Slide 20: Proprietary Products: Aspiring to build $500 million business by FY22
Proprietary Products: Aspiring to build $500 million business by FY22 through lower-risk innovation model Dermatology Specialty Division Design robust patient-centric solutions Medical Dermatology Focus Helping patients manage their disease 7 Products Launched since 2008 Supported by 60 Sa
Slide 21: Optimistic Future
OPTIMISTIC FUTURE e 4 Q
Slide 22: To Summarize:
To Summarize: Top Line Growth with Healthy Profitability Well-positioned for sustained profitable 1 Core business performance remains Strong growth given our strong base business & proven 2 Growth levers are proven, vigorously executed and continue to deliver capability in complex generics with stra
Slide 23: Thank you for being here
Thank you for being here Dr.Reddy’s Qs
Slide 24: Contact
Contact Investor relations Media relations Saunak Savla Calvin Printer [email protected] [email protected] Ph: +91-40-49002135 Ph: +91-40-49002121 About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and i
Dr. Reddy's Laboratories — J.P. Morgan Annual Healthcare Conference 2017 on 6ix